Japan's Daiichi Sankyo halts trials of existing drug for COVID-19 treatment

Japan's Daiichi Sankyo Co said on Tuesday it was halting development of an existing drug for the treatment of COVID-19. Daiichi Sankyo in March started a clinical trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients. The company said in a statement it was discontinuing the trial without citing a reason. The Nikkei newspaper reported that there were safety concerns.

Nafamostat is used in the treatment of pancreatitis and has antiviral properties.

Also Read: Olympics-Japan considers asking Olympic fans for negative COVID tests, vaccinations - Yomiuri

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)